Medical Digest & Congress Report

Professor Gregg Stone explains the results of the FREEDOM COVID Anticoagulation Strategy Randomized Trial. The main conclusions are among non-critically ill pts hospitalized with COVID-19, at 30 days the lower incidence of the primary outcome for therapeutic dose compared with prophylactic dose did not reach statistical significance. However, significantly fewer pts treated with therapeutic-dose d...

Professor Enoch Akowuah explains the results of the UK Mini Mitral Trial. The best surgical approach for mitral valve repair is widely debated. The trial found that Mini MVr is as safe and effective as Sternotomy MVr for DMR. Video: https://medicaldigest.org/scientific-contents/interview:minimally-invasive-versus-conventional-sternotomy-mitral-valve-repair-surgery-uk-mini-mitral-trial

Professor Rachel Lampert explains the findings of LIVE-HCM trial presented at ACC.23/WCC: patients with hypertrophic cardiomyopathy who exercised vigorously did not have an increased incidence of serious cardiac events during three years of follow-up compared to patients who exercised moderately or were inactive. Video: https://medicaldigest.org/scientific-contents/interview:can-patients-hypertrop...

Professor Eliot Brinton, the President, Utah Lipid Center, Salt Lake City explains the results of the research led by Professor Christie Ballantyne, that found MK-0616, an oral PCSK inhibitor, substantially reduced LDL Cholesterol by over 60% at 8 weeks in a clinical trial presented at the American College of Cardiology's 72nd Annual Scientific Session & Expo in New Orleans. Video: https:/...

Professor Gregg Stone explains details on the COAPT trial which set out to assess the safety and efficacy of transcatheter mitral leaflet approximation using MitraClip among symptomatic heart failure patients with secondary mitral regurgitation. In the COAPT trial, compared with GDMT alone, patients with HF and severe secondary mitral regurgitation undergoing TEER with the percutaneous edge-to edg...

Searching for potential cardiovascular risk factors led to many discoveries in the last decades and radically changed our view on CV prevention. Professor Nathan Wong took part in an expert discussion about Lipoprotein(a) at the recent ACC23 Congress. He explained that Lp(a) is an underrecognized genetic risk factor for cardiovascular disease. Elevated levels are seen in approximately 20% of the p...

Professor Marius Hoeper explains the results of a phase 3 trial of sotatercept for treatment of Pulmonary Arterial Hypertension. The conclusion is that in patients with pulmonary arterial hypertension who were receiving stable background therapy, sotatercept resulted in a significant improvement in exercise capacity. Video: https://medicaldigest.org/scientific-contents/interview:sotatercept-combin...

Professor Eliot A. Brinton talks about a new development about the use of Omega-3 fatty acids at the American College of Cardiology and World Congress of Cardiology meeting . The new data support the potential beneficial effects of eicosapentaenoic acid (EPA) in reducing cardiovascular events. In vitro data presentations proves antithrombotic and antioxidant effects of EPA compared to DHA, while m...

Professor Saskia Middeldorp talks about two very important trails were published on LMWH use in pregnancy in 2022. The first one is the Highlow study on the optimal dosing of LMWH in pregnant and post-partum women with the history of VTE. The second one is the ALPINE trial, presented at this year’s ASH congress. Video:  https://medicaldigest.org/scientific-contents/interview:lmwh-use-pregnanc...

Professor Hope Rugo were speaker and co-author of several presentations at this years San Antonio Breast Cancer Symposium. We asked her about early stage HR+, HER2-negative breast cancer. For example, updated results of TAILORx trial on the need for adjuvant chemo and the 42 months data of the MonrachE trial. Video:  https://medicaldigest.org/scientific-contents/interview:treatment-options-ea...

Professor Hope Rugo were speaker and co-author of several presentations at this years San Antonio Breast Cancer Symposium. We asked her about triple negative Breast Cancer. Where is the role of immunotherapy in early triple negative breast cancer? What is the benefit it can provide in the neoadjuvant and post-neoadjuvant setting on the basis of the current scientific evidence? Video:  https:/...

Professor Virginia Kaklamani speak about the novelties and state of the art treatment presented at SABCS 2022. (DESTINY-Breast02 trial Trastuzumab Deruxtecan,  CDK4/6i elacestrant, EMERALD trial, AKT inhibitor capivasertib,POSITIVE trial) Video:  https://medicaldigest.org/scientific-contents/interview:highlights-san-antonio-breast-cancer-symposium-2022

Professor Michael Lincoff shares with us a discussion occurred during the EASD 2022 meeting, this was focusing on the modification of cardiovascular risk in patients with obesity with the GLP-1 receptor agonists. Video: https://congressreport.eu/scientific-contents/interview:targeting-cv-risk-factors-glp-1-ras-people-obesity

Professor Tina Vilsbøll chaired a very interesting session looking into once weekly insulin. Video: https://congressreport.eu/scientific-contents/interview:once-weekly-insulin-onwards-2-study

We asked Professor Silvio Inzucchi about the key messages of the DELIVER study, he talked about this topic at the recent EASD 2022. Video: https://congressreport.eu/scientific-contents/interview:hfpef-hiding-your-practice-key-messages-deliver-study-dapagliflozin-heart-failure-mildly-reduced-or-preserved-ejection-fraction

Domenica Rubino, Director of Washington Center for Weight Management & Research at Arlington, Virginia, USA, held a very interesting lecture about weight control at the recent EASD 2022 Congress. Video:  https://congressreport.eu/scientific-contents/interview:semaglutide-24-mg-improved-glucose-metabolism-and-reverted-prediabetes-normoglycaemia-adults-overweight-or-obesity-vs-liraglutide-3...

Professor Timothy Garvey, Director of Diabetes Research Center at University of Alabama presented new data from the STEP trial program at this year EASD Congress in Stockholm. Video:  https://congressreport.eu/scientific-contents/interview:semaglutide-24-mg-reduces-10-year-type-2-diabetes-risk-people-overweight-or-obesity

Continuous glucose monitoring gives us the opportunity to better analyze diabetes. The new insights help us to improve the therapy of our patients in the active daily life and even during physical exercise. Dr. Othmar Moser held two lectures about this topic the recent EASD 2022 congress. Video:  https://congressreport.eu/scientific-contents/interview:lets-talk-about-cgm-evidence-using-basal-...

Professor Jean-Pascal Machiels Head of the Department of Medical Oncology at the Cliniques Universitaires Sain-Luc, Brussels, presented results of the KEYNOTE-412 trial at this years ESMO Congress. This was a phase 3 study evaluating pembrolizmab with chemoradiation therapy in locally advanced head and neck squamosus cell carcinoma.  Video: https://congressreport.eu/scientific-contents/interv...

Professor John Haanen from the Netherlands Cancer Institute presented the first randomized phase 3 trial on treatment with tumor-infiltrating lymphocytes vs. ipilimumab for advanced melanoma at this years ESMO Congress.  Video:  https://congressreport.eu/scientific-contents/interview:treatment-tumor-infiltrating-lymphocytes-versus-ipilimumab-advanced-melanoma

Professor Ambarish Pandey presented the results a randomised clinical trial about the effect of liraglutide on muscle fat infiltration in overweight or obesity adults at the recent EASD 2022 Congress. We asked him about the result. Video:  https://congressreport.eu/scientific-contents/interview:effect-liraglutide-muscle-fat-infiltration-adults-overweight-or-obesity

Siow Ming Lee, Professor of Medical Oncology at University College London, presented the results of the IPSOS trial at the ESMO 2022 Congress. This was a phase 3 study evaluating first-line atezolizumab vs. single agent chemotherapy in NSCLC patients not eligible for a platinum-based regimen. Video: https://congressreport.eu/scientific-contents/interview:ipsos-trial

Professor Charlotte Suppli Ulrik took part in a very interesting session at this years ERS congress on how to maximize patients outcome in asthma and COPD. We asked her about the topic. Video: https://congressreport.eu/scientific-contents/interview:choices-asthma-and-copd-care-how-maximize-outcomes-patients

Dr John Coghlan going to share his insights with us on evidence - based treatment decisions in pulmonary arterial hypertension. Video:  https://congressreport.eu/scientific-contents/interview:fresh-look-pulmonary-hypertension-practical-takeaways-patient-management

Professor Remo Furtado had an important presentation on the Influenza Vaccine among patients with Acute Coronary Syndromes at this year’s ESC Congress. He is going to share his insights with us on the topic. Video: https://congressreport.eu/scientific-contents/interview:influenza-vaccine-among-patients-acute-coronary-syndromes-vip-acs-trial